Patients are at the heart of everything we do at Loxo Oncology, and we continue to be motivated by one goal: to dramatically improve the lives of people living with cancer by developing medicines against genetically defined targets driving cancer growth.
Advances in human genetics are shedding new light on the molecular roots of disease, and our science is driven by an awareness that every person’s cancer has its own distinct makeup. Like a fingerprint, every person’s tumor is unique. We firmly believe that every patient needs a treatment that takes into account the unique genetic makeup of his or her cancer.
We focus on developing selective medicines for cancers that are driven by a defining genetic alteration, a so-called oncogenic driver. By turning off the mechanism that is driving the cancer, we aim to reduce tumor volume and growth. The success of this approach relies heavily on our ability to create medicines that attack very specific gene variations and identify the patients who are most likely to benefit from these targeted therapies. We believe that this strategy can lead to rapid and profound clinical results for patients.
We invite you to visit our resources page, complete with useful information and external resources for cancer patients and their caregivers. Our Pipeline section contains information on our programs and their development progress. For additional information about any of the larotrectinib (LOXO-101) clinical trials, please refer to www.clinicaltrials.gov. Interested patients and physicians can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123.